Selective activators of thyroid hormone receptors

Area of Science:

• Endocrinology
• Molecular Pharmacology
• Metabolic Disorders

Background:

• Thyroid hormone (TH) excess causes both beneficial (e.g., weight loss, reduced cholesterol) and detrimental effects (e.g., increased heart rate, muscle wasting).
• Nuclear thyroid hormone receptors (TRs) mediate all TH actions, with different TR isoforms contributing uniquely to specific effects.
• Genetic evidence indicates that TR isoform selectivity is key to dissociating beneficial from harmful TH actions.

Purpose of the Study:

• To review novel selective TR activators.
• To elucidate their mechanism of action, focusing on TR-beta isoform targeting.
• To summarize their effects in preclinical animal models.

Main Methods:

• Review of scientific literature on selective TR activators.
• Analysis of studies detailing TR isoform-selective compound mechanisms.
• Examination of data from animal models assessing efficacy and safety.

Main Results:

• New selective TR activators targeting the TR-beta isoform have been developed.
• These compounds demonstrate potential to selectively activate beneficial TH pathways.
• Animal models show promise for treating lipid disorders and obesity with these agents.

Conclusions:

• Selective TR-beta activators represent a promising therapeutic strategy.
• They offer a potential to harness beneficial TH effects for metabolic diseases.
• These compounds may provide a novel treatment for hyperlipidemia and obesity.